A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2366 participants.
Also called NCT03766581
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 2,366 participants
- Sponsor
- Registry
-
NCT03766581
-
- Other papers using this trial's data
- Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Mexico, Norway, Poland, Russia, South Korea, Spain, Sweden, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03766581. Randomized; quadruple masking; primary purpose prevention. Start 2019-01-27 (actual); primary completion 2022-03-31 (actual). Results posted on 2023-06-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
- Acronym
- AXIOMATIC-SSP
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- BMS-986177
- Intervention (Other)
- Placebo
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Bristol-Myers Squibb
- Collaborator
- Janssen, LP
Record details
- Record id
cardio:ct-nct03766581- Content hash
e71004eb0efabb464b7dc81a9aa6542b79e978553344e949ecb4b6fa4c294d11